More than 500 adverse neuropsychiatric reactions have been reported in children under the age of nine involving an asthma drug which is to get new warnings over its risks. The Medicines and Healthcare products Regulatory Agency (MHRA) announced last week that more prominent warnings would be added to the information leaflet provided with the asthma drug montelukast, sold under the brand name Singulair.
Read more
